R & d- multi-antigen vaccine for lung cancer prevention

Ended Awarded Last action

Contract number
HHSN26100009
Awardee
Awarding agency
Obligated
$907,864

Award facts

Opportunity
Contract value 100% obligated
$907,864.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
541711 Research and Development in Biotechnology
PSC
AN11 Health R&D Services; Health Care Services; Basic Research
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
Pricing
Firm Fixed Price
Place of performance
Oklahoma City, OK 73104, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Close Out 4 -$5,424
Other Administrative Action 3 $0
Other Administrative Action 1 $0
Additional Work (new agreement, FAR part 6 applies) 2 · Multi-antigen vaccine for lung cancer preventionpop: 09/18/2014-09/17/2016HHSN261201200013IPRECLINICAL efficacy and intermediate endpoint biomarkers $28,757
Original award $884,531

Quick answers

Who was awarded contract HHSN26100009?

HHSN26100009 was awarded to University Of Oklahoma by National Cancer Institute (National Institutes of Health) on September 18, 2014.

How much is contract HHSN26100009 worth?

The government has obligated $907,864 on HHSN26100009.

Is contract HHSN26100009 an order under another contract?

Yes. HHSN26100009 is a delivery order under HHSN261201200013I, an indefinite delivery contract, on Preclinical Efficacy and Intermediate Endpoint Biomarkers.

Was contract HHSN26100009 competed?

The extent of competition for HHSN26100009 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login